Emory University
Atlanta, United States
Team details appear once the team leader joins.
Is this your team? Claim it
Sickle cell disease
FollowWhat is new in Sickle cell disease research, which clinical trials are open, and who works on it. From public registries and PubMed, with the source and date of every fact.
Cure status
- 20vPCVPhase 3 · NCT07247188
- bb1111Phase 3 · NCT04293185
- CrizanlizumabPhase 3 · NCT06439082 · NCT05469828
- Crizanlizumab (SEG101)Phase 3 · NCT03814746
- CTX001Phase 3 · NCT05329649 · NCT05477563 · NCT04208529
- EtavopivatPhase 3 · NCT06612268 · NCT06198712 · NCT05953584
- Etavopivat APhase 3 · NCT06609226
- Etavopivat BPhase 3 · NCT06609226
- Etavopivat CPhase 3 · NCT06609226
- Etavopivat TabletsPhase 3 · NCT04624659
- Etavopivat Tablets High dosePhase 3 · NCT04624659
- Etavopivat Tablets Low dosePhase 3 · NCT04624659
- Haploidentical stem cell transplantationPhase 3 · NCT05392894
- HydroxyureaPhase 3 · NCT03948867 · NCT05357482 · NCT03653338 · NCT01966731 · NCT03077542 · NCT01962415 · NCT07616154 · NCT05953584 · NCT05285917 · NCT06171217 · NCT05662098
- IloprostPhase 3 · NCT07498309
- Ketamine hydrochloride injectionPhase 3 · NCT07450430
- L-citrullinePhase 3 · NCT06635902 · NCT06989567
- LidocainPhase 3 · NCT07274254
- MitapivatPhase 3 · NCT07656415 · NCT04610866 · NCT05031780
- Mitapivat Matched PlaceboPhase 3 · NCT07656415
- MorphinePhase 3 · NCT06315920
- ParecoxibPhase 3 · NCT06315920
- PCV21Phase 3 · NCT07247188
- Red Blood CellPhase 3 · NCT04084080
- RilzabrutinibPhase 3 · NCT06975865
- Tocilizumab (RoActemra®, 20 mg/mL).Phase 3 · NCT06818266
- OsivelotorPhase 2/3 · NCT05431088
- [13N]NH3Phase 2 · NCT05583721
- 25 mg/day zincPhase 2 · NCT06260891
- 40 mg/day zincPhase 2 · NCT06260891
- AbataceptPhase 2 · NCT06145282 · NCT03924401 · NCT07616154 · NCT07599176
- AlemtuzumabPhase 2 · NCT01499888 · NCT02105766 · NCT06872333 · NCT06358638 · NCT04018937 · NCT05357482 · NCT03653338 · NCT00061568 · NCT05384756 · NCT03077542 · NCT01962415 · NCT07616154 · NCT00977691 · NCT07599176 · NCT03214354
- Alemtuzumab, low dose total body irradiation, SirolimusPhase 2 · NCT03587272
- Alendronate SodiumPhase 2 · NCT06016634
- alpha beta depletionPhase 2 · NCT04099966
- AnumigilimabPhase 2 · NCT07224360
- ATGPhase 2 · NCT03121001
- Autologous CD34+ HSC cells transduced with the lentiviral vector containing a shRNA targeting BCL11aPhase 2 · NCT05353647
- AzathioprinePhase 2 · NCT07616154
- BortezomibPhase 2 · NCT05736419
- BusulfanPhase 2 · NCT06506461 · NCT06872333
- CD34 selected T-cell depleted allogeneic SCTPhase 2 · NCT01461837
- Cell InfusionPhase 2 · NCT06872333
- CSL889Phase 2 · NCT06699849
- CyclophosphamidePhase 2 · NCT06145282 · NCT02105766 · NCT06872333 · NCT03249831 · NCT03077542 · NCT03121001 · NCT05736419 · NCT00977691
- Cyclophosphamide 50mgPhase 2 · NCT07616154
- CyclosporinePhase 2 · NCT04018937
- DaratumumabPhase 2 · NCT06358638
- DeferasiroxPhase 2 · NCT07023666
- DeferipronePhase 2 · NCT07023666
- DeferoxaminePhase 2 · NCT07023666
- DefibrotidePhase 2 · NCT02675959
- DexamethasonePhase 2 · NCT05736419
- DronabinolPhase 2 · NCT05519111
- EchocardiographyPhase 2 · NCT07023666
- Electrocardiogram (ECG)Phase 2 · NCT07023666
- Empagliflozin (oral)Phase 2 · NCT07175051
- FilgrastimPhase 2 · NCT06145282 · NCT02105766 · NCT03077542 · NCT07616154
- FludarabinePhase 2 · NCT06872333 · NCT04018937 · NCT03653338 · NCT03121001 · NCT05736419 · NCT01962415
- Hematopoietic Progenitor Cell InfusionPhase 2 · NCT07616154
- HydroxycarbamidPhase 2 · NCT06578507
- hydroxyurea, azathioprine, alemtuzumab, thioptepa, low dose total body irradiation and sirolimusPhase 2 · NCT04362293
- hydroxyurea, azathioprine, alemtuzumab, thiotepa, plerixafor, low dose total body irradiation, cyclophosphamide and sirolimusPhase 2 · NCT04362293
- IMR-687Phase 2 · NCT04053803
- LexiscanPhase 2 · NCT05583721
- MelphalanPhase 2 · NCT04018937 · NCT01962415
- MethotrexatePhase 2 · NCT04018937
- Mycophenolate MofetilPhase 2 · NCT06872333 · NCT03249831 · NCT03121001 · NCT05736419
- Normal Saline Placebo InfusionPhase 2 · NCT07369024
- PentostatinPhase 2 · NCT02105766 · NCT03249831 · NCT03077542
- Plerixafor (mozobil)Phase 2 · NCT06872333
- Rabbit ATGPhase 2 · NCT05736419
- RadiotherapyPhase 2 · NCT02105766
- RituximabPhase 2 · NCT03653338 · NCT05736419
- SenicapocPhase 2 · NCT07282210
- SirolimusPhase 2 · NCT06145282 · NCT01499888 · NCT02105766 · NCT06872333 · NCT06358638 · NCT05357482 · NCT00061568 · NCT05384756 · NCT03077542 · NCT03121001 · NCT07616154 · NCT00977691 · NCT07015684 · NCT03214354
- Stem cell infusionPhase 2 · NCT03121001
- Sub-dissociative Ketamine InfusionPhase 2 · NCT07369024
- TacrolimusPhase 2 · NCT06872333 · NCT04018937 · NCT03249831 · NCT05736419
- TBIPhase 2 · NCT05357482 · NCT07616154
- TebapivatPhase 2 · NCT06924970
- Tebapivat Matched PlaceboPhase 2 · NCT06924970
- ThiotepaPhase 2 · NCT03653338 · NCT01962415 · NCT07616154
- ThymoglobulinPhase 2 · NCT06872333
- TocilizumabPhase 2 · NCT05640271
- Total Body IrradiationPhase 2 · NCT06872333 · NCT06358638 · NCT03121001 · NCT07599176 · NCT07015684 · NCT03214354
- Allogeneic Non-Myeloablative Stem Cell TransplantationPhase 1/2 · NCT01499888
- anti-inflammatory therapyPhase 1/2 · NCT07432867
- ArgininePhase 1/2 · NCT02447874
- Arginine (Continuous)Phase 1/2 · NCT02447874
- Arginine (Loading)Phase 1/2 · NCT02447874
- Aspirin 100mgPhase 1/2 · NCT06417411
- BEAM-101Phase 1/2 · NCT05456880
- Benserazide Only ProductPhase 1/2 · NCT04432623
- BMS-986470Phase 1/2 · NCT06481306
- BriquilimabPhase 1/2 · NCT06145282 · NCT05357482
- CannabidiolPhase 1/2 · NCT06930703
- CD3/CD19 depleted leukocytesPhase 1/2 · NCT03653338
- CD34 Stem Cell Selection TherapyPhase 1/2 · NCT01966367
- CD45RA depleted leukocytesPhase 1/2 · NCT03653338
- CliniMACS CD34 ReagentPhase 1/2 · NCT04008368
- CRISPR_SCD001Phase 1/2 · NCT04774536
- DREAM01 drug productPhase 1/2 · NCT07432867
- Drug Product is administered by IV infusion following myeloablative conditioning with busulfanPhase 1/2 · NCT06399107
- EDIT-301Phase 1/2 · NCT04853576
- FamotidinePhase 1/2 · NCT06481306
- Filgrastim (G-CSF)Phase 1/2 · NCT05357482
- GVHD prophylaxis regimenPhase 1/2 · NCT03128996
- haploidentical stem cell transplantPhase 1/2 · NCT03077542
- hydroxycarbamidePhase 1/2 · NCT07708714
- ITU512Phase 1/2 · NCT06546670
- Low Dose IrradiationPhase 1/2 · NCT00977691
- nula-cel Drug ProductPhase 1/2 · NCT04819841
- PantoprazolePhase 1/2 · NCT06481306
- PBSC TransplantPhase 1/2 · NCT00977691
- Peripheral blood hematopoietic progenitor cell (PBPC) transplantPhase 1/2 · NCT00061568
- Peripheral blood hematopoietic progenitor cell ApheresisPhase 1/2 · NCT00061568
- PlerixaforPhase 1/2 · NCT03664830 · NCT06506461 · NCT05357482
- Plerixafor Dose EscalationPhase 1/2 · NCT07341022
- Red cell units that are genotype matched at the RHD and RHCE lociPhase 1/2 · NCT04156893
- RIC regimenPhase 1/2 · NCT03128996
- RuxolitinibPhase 1/2 · NCT07252050
- 131I-apamistmabPhase 1 · NCT07015684
- autologous bone marrow derived CD34+ HSPCs electroporated with BCL11A enhancer targeting Cas9 ribonucleoproteinPhase 1 · NCT07708350 · NCT06647979
- Buprenorphine Buccal Film [Belbuca]Phase 1 · NCT07799571
- CampathPhase 1 · NCT07015684
- CD4+ T-cell-depleted Haploidentical Hematopoietic TransplantPhase 1 · NCT03249831
- DISC-3405Phase 1 · NCT07187973
- Exchange TransfusionPhase 1 · NCT07015684
- Extended-Release MethylphenidatePhase 1 · NCT07226219
- FostamatinibPhase 1 · NCT05904093
- Gene-modified CD34+ cellsPhase 1 · NCT06506461
- Hematopoietic Cell TransplantationPhase 1 · NCT05384756
- Intensity-Modulated Radiation TherapyPhase 1 · NCT05384756
- MinocyclinePhase 1 · NCT05605366
- MotixafortidePhase 1 · NCT06506461 · NCT06442761
- NicotinamidePhase 1 · NCT04055818
- OTQ923Phase 1 · NCT06155500
- panobinostatPhase 1 · NCT01245179
- Planar gamma imagingPhase 1 · NCT07015684
- Rabbit anti-thymocyte globulinPhase 1 · NCT03249831
- Sequencing Assay for Variant rs114518452Phase 1 · NCT07708350 · NCT06647979
- single infusion of autologous bone marrow derived CD34+ HSC cells transduced with the lentiviral vector containing a short-hairpin RNA targeting BCL11aPhase 1 · NCT03282656
- VAS-101Phase 1 · NCT07566494
- Biotin-labeled red blood cellsEarly phase 1 · NCT06313398
- CS-206Early phase 1 · NCT06565026 · NCT07000318
- YOLT-204Early phase 1 · NCT07190001
Closest to patients
- Study of Two Doses of Crizanlizumab Versus Placebo in Adolescent and Adult Sickle Cell Disease PatientsStudy of Two Doses of Crizanlizumab Versus Placebo in Adolescent and Adult Sickle Cell Disease PatientsNovartis Investigative Site · Essen, Germany + 51 more hospitalsPhase 3Primary completion 2022
- A Study Evaluating the Efficacy and Safety of Mitapivat (AG-348) in Participants With Sickle Cell Disease (RISE UP)A Study Evaluating the Efficacy and Safety of Mitapivat (AG-348) in Participants With Sickle Cell Disease (RISE UP)University Health Network · Toronto, Canada + 87 more hospitalsPhase 2/3Primary completion 2025
- A Study of Etavopivat in Adults and Adolescents With Sickle Cell Disease (HIBISCUS)A Study of Etavopivat in Adults and Adolescents With Sickle Cell Disease (HIBISCUS)Hammersmith Hospital London · London, United Kingdom + 129 more hospitalsPhase 3Results expected 2026
Let us optimize your content
Apply for experimental treatment or a research study
The trial team decides who can take part; your doctor can help you ask.
Distance is calculated in your browser. Your city is not sent to us.
Loading trial sites…
Latest news
Results, new trials and publications, newest first. Every item links to its source.
Results and new studies, newest first, in plain words.
Plain-language summary pending. Original title shown.
Publication
Antinociceptive interaction of Δ9-tetrahydrocannabinol and cannabidiol in a humanized mouse model of sickle cell disease.
Antinociceptive interaction of Δ9-tetrahydrocannabinol and cannabidiol in a humanized mouse model of sickle cell disease.
The Journal of pharmacology and experimental therapeutics
PubMed · PMID 42874273Publication
Vitamin D Deficiency as a Potential Modifier of Hematological Outcomes and Vaso-Occlusive Crisis Frequency in Sickle Cell Disease: Evidence from a Sudanese Cohort.
Vitamin D Deficiency as a Potential Modifier of Hematological Outcomes and Vaso-Occlusive Crisis Frequency in Sickle Cell Disease: Evidence from a Sudanese Cohort.
Biomedicines
PubMed · PMID 42652102
Find fellow researchers
Groups with active Sickle cell disease work.
St. Jude Children's Research Hospital
Memphis, United States
Team details appear once the team leader joins.
Is this your team? Claim it
Inserm
Paris, France
Team details appear once the team leader joins.
Is this your team? Claim it
Assistance Publique – Hôpitaux de Paris
Paris, France
Team details appear once the team leader joins.
Is this your team? Claim it
Harvard University
Cambridge, United States
Team details appear once the team leader joins.
Is this your team? Claim it
Johns Hopkins University
Baltimore, United States
Team details appear once the team leader joins.
Is this your team? Claim it
Children's Healthcare of Atlanta
Atlanta, United States
Team details appear once the team leader joins.
Is this your team? Claim it
Cincinnati Children's Hospital Medical Center
Cincinnati, United States
Team details appear once the team leader joins.
Is this your team? Claim it
Children's Hospital of Philadelphia
Philadelphia, United States
Team details appear once the team leader joins.
Is this your team? Claim it
University of Pittsburgh
Pittsburgh, United States
Team details appear once the team leader joins.
Is this your team? Claim it
University of Illinois Chicago
Chicago, United States
Team details appear once the team leader joins.
Is this your team? Claim it
Duke University
Durham, United States
Team details appear once the team leader joins.
Is this your team? Claim it